CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer
Open Access
- 14 August 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (50) , 87244-87262
Abstract
CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancerKeywords
This publication has 46 references indexed in Scilit:
- Macrophages hijack anti-PD-1 therapyNature Reviews Clinical Oncology, 2017
- Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.2015
- Tissue-based map of the human proteomeScience, 2015
- Innate Immunity Components and Cytokines in Gastric Mucosa in Children with Helicobacter pylori InfectionMediators of Inflammation, 2015
- Phylogeny of suckermouth catfishes (Mochokidae: Chiloglanis) from Kenya: The utility of Growth Hormone introns in species level phylogeniesMolecular Phylogenetics and Evolution, 2014
- Monocyte/macrophage‐derived soluble CD163: a novel biomarker in multiple myelomaEuropean Journal of Haematology, 2014
- IL-21 Promotes CD4 T Cell Responses by Phosphatidylinositol 3-Kinase–Dependent Upregulation of CD86 on B CellsThe Journal of Immunology, 2014
- Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinomaCancer Science, 2010
- Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II MelanomaJournal of Clinical Oncology, 2009
- Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549Life Sciences, 2004